• Share to Facebook
    • Twitter
    • Email
    • Print

May 5, 2014

HSI/India Applauds Drug Controller’s Vision to Replace Animals in Pharmaceutical Testing

Humane Society International/India

  • Shutterstock

Humane Society International/India welcomes recent statements by Dr. G.N. Singh, India’s Drug Controller General and head of the Central Drug Standard Control Organization, that he is giving serious consideration to modernizing India’s pharmaceutical safety assessment by replacing old-fashioned animal testing with modern non-animal alternatives.

The CDSCO has dedicated 2014 to ‘Human safety and animal safety’ as part of its vision to protect animals used in laboratories in addition to safeguarding the interests of human patients.

Alokparna Sengupta, HSI/India’s research & toxicology campaign manager, said; “Dr. Singh is showing visionary leadership in his efforts to implement transformational change in India’s science infrastructure. Moving away from outdated and unethical animal tests and aligning India’s pharmaceutical regulations with those of other leading economies is a step forward for human health, industry and animals alike. Humane Society International has successfully worked with governments and scientists across Europe, North America and beyond, and we look forward to working with Dr. Singh’s office to advance 21st century safety science in India, too.”

Nine out of ten experimental drugs that appear safe or effective in animal tests go on to fail in human patients because too many biological and physiological differences between the species exist for these methods to be reliable.

HSI/India has conducted a series of workshops and conferences across India, presenting the expertise of international scientists in modern chemical and pharmaceutical toxicity testing. At a recent science workshop in Hyderabad hosted by HSI and the Committee for the Purpose of Control and Supervision of Experiments on Animals, HSI’s President Andrew Rowan, Ph.D. spoke to more than 50 scientists about ‘Tox21’ – the transition to high-tech, human biology-based safety testing.

Dr. Singh was reported in PharmaBiz as stating, “We envision to protect the lives of all the living beings in the country and for that all steps will be taken pro-actively to enhance good governance by strengthening regulatory mechanism further. We understand that experiments on animals are unethical and cruel and we are going to make sure that all steps are being taken to avoid cruelty against animals by ensuring stringent adoption of good laboratory practices (GLP) in all the manufacturing units across the country and also while conducting clinical trials etc.”

Watch HSI’s video 21st Century Science here.

ENDS

Media Contact:

HSI/India: Navamita Mukherjee, nmukherjee@hsi.org, +919985472760

Notes
Andersen ME, Krewski D. Toxicological Sciences 2009;107:324-30.

  • Sign Up
  • Take Action
Media Contact List2